News AbbVie and J&J claim new Imbruvica okay in US AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
News AbbVie's Venclyxto approved in Europe in CLL AbbVie blood cancer drug tipped to be a blockbuster.
News NICE rejects Roche drug in follicular lymphoma NICE uncertain over survival data for Gazyvaro and bendamustine.
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Wave's stock wavers on obesity drug data Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.